Hrison Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 6.50 M
- Paid Up Capital ₹ 5.60 M
- Company Age 19 Year, 11 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.00 Cr
- Revenue Growth 21.81%
- Profit Growth -50.22%
- Ebitda -43.12%
- Net Worth 7.98%
- Total Assets -9.30%
About Hrison Pharmachem
Hrison Pharmachem Private Limited (HPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 February 2006 and has a history of 19 years. Its registered office is in Mumbai-9, Maharashtra.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.50 M and a paid-up capital of Rs 5.60 M.
The company currently has active open charges totaling ₹4.00 Cr.
Haresh Doshi, Aarti Doshi, and Krupa Doshi serve as directors at the Company.
Company Details
- Location Mumbai-9, Maharashtra
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231MH2006PTC159736
- Company No.
159736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Feb 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Hrison Pharmachem?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krupa Doshi  | Director | 25-Mar-2012 | Current |
| Haresh Doshi | Director | 10-Feb-2006 | Current |
| Aarti Doshi | Director | 10-Feb-2006 | Current |
Financial Performance of Hrison Pharmachem.
Hrison Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 21.81% increase. The company also saw a substantial fall in profitability, with a 50.22% decrease in profit. The company's net worth moved up by a moderate rise of 7.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hrison Pharmachem?
In 2023, Hrison Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹40.00 M
₹0
Charges Breakdown by Lending Institutions
- The Ratnakar Bank Limited : 2.50 Cr
- Rajkot Nagarik Sahakari Bank Limited : 1.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Aug 2011 | The Ratnakar Bank Limited | ₹2.50 Cr | Open |
| 13 Apr 2009 | Rajkot Nagarik Sahakari Bank Limited | ₹1.50 Cr | Open |
How Many Employees Work at Hrison Pharmachem?
Unlock and access historical data on people associated with Hrison Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hrison Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hrison Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
